Circulation. 2008;118:e676
doi: 10.1161/CIRCULATIONAHA.108.780817
(Circulation. 2008;118:e676.)
© 2008 American Heart Association, Inc.
Response to Letter Regarding Article, "Renal Vasodilatory Action of Dopamine in Patients With Heart Failure: Magnitude of Effect and Site of Action"
Uri Elkayam, MD;
Tien M.H. Ng, PharmD;
Parta Hatamizadeh, MD;
Munir Janmohamed, MD;
Anilkumar Mehra, MD
Division of Cardiology, University of Southern California, Keck School of Medicine, Los Angeles, Calif
Drs Lema and Canessa point out the important intersubject variability of plasma levels of dopamine, which has been shown in normal volunteers. These differences may also be related to the interpatient variability in dopamine dose producing the largest effect on renal blood flow. In our study,1 5 patients demonstrated a maximal increase in renal blood flow at a dopamine dose
3 µg · kg–1 · min–1, whereas 3 patients demonstrated a maximal increase in renal blood flow at a dose of 5 µg · kg–1 · min–1, and 5 patients demonstrated a maximal increase in renal blood flow at dose of 10 µg · kg–1 · min–1. The majority of the patients, therefore, exhibited the greatest response to dopamine at doses greater than the traditional "renal dose."
 |
Acknowledgments
|
|---|
Disclosures
None.
 |
Reference
|
|---|
1. Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action.
Circulation. 2008; 117: 200–205.
[Abstract/Free Full Text]